Fortress Biotech, Inc. (FBIO)

Oncology Corporate Profile

Stock Performance

3.8400
0.0000

HQ Location

3 Columbus Circle, 15th Floor
New York, NY 10019

Company Description

Fortress Biotech, Inc. (“Fortress” or “the Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as Fortress Companies. The Company will leverage its biopharmaceutical business expertise and drug development capabilities to help the Fortress Companies achieve their goals.

Website: http://www.fortressbiotech.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CNDO-109natural killer cell stimulantAcute Myelogenous Leukemia (AML)I

View additional information on product candidates here »

Source


http://www.fortressbiotech.com

Recent News Headlines

Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017

3/20/2017 12:00 pm

[GlobeNewswire] - NEW YORK, March 20, 2017-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that preclinical data on its anti-PD-L1 antibody and EGFR inhibitor programs will be presented in poster ...

Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016

3/16/2017 08:00 pm

[GlobeNewswire] - NEW YORK, March 16, 2017-- Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced financial ...

Fortress Biotech Forms New Subsidiary, Cyprium Therapeutics, Inc., to Develop Novel Therapies for Menkes Disease and Related Copper Metabolism Disorders

3/14/2017 11:03 am

[GlobeNewswire] - Cyprium, NICHD establish CRADA to advance clinical development of Phase 3 candidate CUTX-101 in Menkes disease, a rare and fatal pediatric disease. Cyprium licenses preclinical AAV-ATP7A gene therapy from ...

Fortress Biotech to Present at the 29th Annual ROTH Conference

3/9/2017 01:00 pm

[GlobeNewswire] - NEW YORK, March 09, 2017-- Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that ...

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101

2/28/2017 01:00 pm

[GlobeNewswire] - NEW YORK, Feb. 28, 2017-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that the U.S. Patent and Trademark Office has issued a composition of matter patent for CK-101, Checkpoint’ ...

Fortress Biotech Announces that its Subsidiary, Mustang Bio, Closes $94.5 Million Private Placement Financing

2/2/2017 12:03 pm

[GlobeNewswire] - NEW YORK, Feb. 02, 2017-- Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that ...

National Holdings’ OPN Capital Markets Closes $94.5 Million Private Placement Financing for Mustang Bio, Inc., a Subsidiary of Fortress Biotech

2/2/2017 12:03 pm

[GlobeNewswire] - NEW YORK, Feb. 02, 2017-- OPN Capital Markets, the healthcare related investment banking and research division of National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation, ...

Fortress Biotech Form New Subsidiary, Caelum Biosciences, Inc., to Develop Novel Treatment for Al Amyloidosis

1/4/2017 01:04 pm

[at noodls] - FORTRESS BIOTECH FORMS NEW SUBSIDIARY, CAELUM BIOSCIENCES, INC., TO DEVELOP NOVEL TREATMENT FOR AL AMYLOIDOSIS Caelum Program Evaluating CAEL?101 (11?1F4) for AL Amyloidosis In?licensed from Columbia University ...

Fortress Biotech Forms New Subsidiary, Caelum Biosciences, Inc., to Develop Novel Treatment for AL Amyloidosis

1/4/2017 01:00 pm

[GlobeNewswire] - Caelum Program Evaluating CAEL-101 for AL Amyloidosis In-licensed from Columbia University. Data from ongoing Phase 1 a/1b study of CAEL-101 presented by Dr. Suzanne Lentzsch at ASH have demonstrated CAEL-101 ...

Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol

1/3/2017 02:01 pm

[at noodls] - New York, NY - January 3, 2017 - Avenue Therapeutics, Inc. ("Avenue"), a Fortress Biotech (NASDAQ: FBIO) Company, today announced that Notices of Allowance have now been received from the U.S. ...

Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol

1/3/2017 01:00 pm

[GlobeNewswire] - NEW YORK, Jan. 03, 2017-- Avenue Therapeutics, Inc., a Fortress Biotech Company, today announced that Notices of Allowance have now been received from the U.S. Patent and Trademark Office for two patent ...